drugset
drugset / Trial / NCT05374538

VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer

NCT05374538 ↗

Phase 1 Terminated 3 enrolled Vitrac Therapeutics, LLC Westat · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a Phase 1a/1b study of aurora kinase A inhibitor VIC-1911 administered as monotherapy and in combination with sotorasib for the treatment of locally advanced or metastatic KRAS G12C-mutant non-small cell lung cancer(NSCLC).

Timeline

Start
2022-11-09
Primary completion
2023-08-26
Completion
2023-08-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Sotorasib Small molecule 960 mg Oral
Subject VIC-1911 Unknown 75 mg Oral

Indications

non-small cell lung carcinoma